share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q:2024財年三季報
美股SEC公告 ·  2024/11/09 05:07

Moomoo AI 已提取核心訊息

Revelation Biosciences reported a Q3 2024 net loss of $2.2 million, compared to a $2.6 million loss in Q3 2023. Revenue remained at zero while research and development expenses decreased to $0.8 million from $1.7 million YoY. The company ended the quarter with cash and cash equivalents of $6.5 million.The company raised $9.2 million during the first nine months through financing activities, including $5.4 million from a February 2024 public offering and $3.5 million from warrant inducement. Research and development efforts focused on advancing GEM-AKI for acute kidney injury, GEM-CKD for chronic kidney disease, and GEM-PSI for post-surgical infection prevention.Management expressed substantial doubt about the company's ability to continue as a going concern, noting current cash reserves will not sustain operations for the next 12 months. Additionally, Revelation received a Nasdaq delisting notice in October 2024 for failing to maintain the minimum bid price requirement, though the company has appealed and is pursuing compliance measures.
Revelation Biosciences reported a Q3 2024 net loss of $2.2 million, compared to a $2.6 million loss in Q3 2023. Revenue remained at zero while research and development expenses decreased to $0.8 million from $1.7 million YoY. The company ended the quarter with cash and cash equivalents of $6.5 million.The company raised $9.2 million during the first nine months through financing activities, including $5.4 million from a February 2024 public offering and $3.5 million from warrant inducement. Research and development efforts focused on advancing GEM-AKI for acute kidney injury, GEM-CKD for chronic kidney disease, and GEM-PSI for post-surgical infection prevention.Management expressed substantial doubt about the company's ability to continue as a going concern, noting current cash reserves will not sustain operations for the next 12 months. Additionally, Revelation received a Nasdaq delisting notice in October 2024 for failing to maintain the minimum bid price requirement, though the company has appealed and is pursuing compliance measures.
Revelation Biosciences報告2024年第三季度淨虧損220萬美元,而2023年第三季度虧損爲260萬美元。營業收入保持爲零,而研發費用從去年的170萬美元減少至80萬美元。公司在季度末的現金及現金等價物爲650萬美元。公司在前九個月通過融資活動籌集了920萬美元,其中包括2024年2月公開募股的540萬美元和350萬來自於權證誘導的資金。研發工作重點推進GEm-AKI用於急性腎損傷、GEm-CKD用於慢性腎病和GEm-PSI用於術後感染預防。管理層對公司持續經營能力表達了重大懷疑,並指出當前的現金儲備無法支撐未來12個月的運營。此外,Revelation在2024年10月收到了納斯達克的退市通知,因未能維持最低買盤價格要求,儘管公司已提出上訴並在尋求合規措施。
Revelation Biosciences報告2024年第三季度淨虧損220萬美元,而2023年第三季度虧損爲260萬美元。營業收入保持爲零,而研發費用從去年的170萬美元減少至80萬美元。公司在季度末的現金及現金等價物爲650萬美元。公司在前九個月通過融資活動籌集了920萬美元,其中包括2024年2月公開募股的540萬美元和350萬來自於權證誘導的資金。研發工作重點推進GEm-AKI用於急性腎損傷、GEm-CKD用於慢性腎病和GEm-PSI用於術後感染預防。管理層對公司持續經營能力表達了重大懷疑,並指出當前的現金儲備無法支撐未來12個月的運營。此外,Revelation在2024年10月收到了納斯達克的退市通知,因未能維持最低買盤價格要求,儘管公司已提出上訴並在尋求合規措施。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息